Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-02

Clinical Trial Update: Dysport in Hallux Abducto Valgus (HAV) Phase IIa [Phase 2]

View source ↗

Summary

Phase IIa clinical trial of Dysport for hallux abductovarus (hallux valgus) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Hallux Abducto Valgus | Phase 2 | Status: COMPLETED | Results posted: 2021-07-02